Associated Papers
Peroxisome proliferator-activated receptor gamma mutation in familial partial lipodystrophy type three: A case report and review of literature.
Wu CJ et al.
World Journal of Diabetes, 2024
Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.
Soares RMV et al.
Frontiers in Endocrinology, 2024
Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.
Chen X et al.
Frontiers in Endocrinology, 2022
Genetics and Clinical Characteristics of PPARγ Variant-Induced Diabetes in a Chinese Han Population.
Gong S et al.
Frontiers in Endocrinology, 2021
34764936 (PubMed )
Supplement: DataSheet_2.docx
Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
Shoaito H et al.
Journal of Cellular and Molecular Medicine, 2020
Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.
Broekema MF et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 2019
Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
Broekema MF et al.
Molecular Metabolism, 2019
Select a paper to view details